Cargando…

Development of a Novel Red Clay-Based Drug Delivery Carrier to Improve the Therapeutic Efficacy of Acyclovir in the Treatment of Skin Cancer

Acyclovir (ACV) is a promising candidate for drug repurposing because of its potential to provide an effective treatment for viral infections and non-viral diseases, such as cancer, for which limited treatment options exist. However, its poor physicochemical properties limit its application. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Francis, Arul Prakash, Ahmad, Aftab, Nagarajan, Sri Durga Devi, Yogeeswarakannan, Harish Sundar, Sekar, Krishnaraj, Khan, Shah Alam, Meenakshi, Dhanalekshmi Unnikrishnan, Husain, Asif, Bazuhair, Mohammed A., Selvasudha, Nandakumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383537/
https://www.ncbi.nlm.nih.gov/pubmed/37514105
http://dx.doi.org/10.3390/pharmaceutics15071919
_version_ 1785080934866878464
author Francis, Arul Prakash
Ahmad, Aftab
Nagarajan, Sri Durga Devi
Yogeeswarakannan, Harish Sundar
Sekar, Krishnaraj
Khan, Shah Alam
Meenakshi, Dhanalekshmi Unnikrishnan
Husain, Asif
Bazuhair, Mohammed A.
Selvasudha, Nandakumar
author_facet Francis, Arul Prakash
Ahmad, Aftab
Nagarajan, Sri Durga Devi
Yogeeswarakannan, Harish Sundar
Sekar, Krishnaraj
Khan, Shah Alam
Meenakshi, Dhanalekshmi Unnikrishnan
Husain, Asif
Bazuhair, Mohammed A.
Selvasudha, Nandakumar
author_sort Francis, Arul Prakash
collection PubMed
description Acyclovir (ACV) is a promising candidate for drug repurposing because of its potential to provide an effective treatment for viral infections and non-viral diseases, such as cancer, for which limited treatment options exist. However, its poor physicochemical properties limit its application. This study aimed to formulate and evaluate an ACV-loaded red clay nanodrug delivery system exhibiting an effective cytotoxicity. The study focused on the preparation of a complex between ACV and red clay (RC) using sucrose stearate (SS) (nanocomplex F1) as an immediate-release drug-delivery system for melanoma treatment. The synthesized nanocomplex, which had nanosized dimensions, a negative zeta potential and the drug release of approximately 85% after 3 h, was found to be promising. Characterization techniques, including FT-IR, XRD and DSC-TGA, confirmed the effective encapsulation of ACV within the nanocomplex and its stability due to intercalation. Cytotoxicity experiments conducted on melanoma cancer cell lines SK-MEL-3 revealed that the ACV release from the nanocomplex formulation F1 effectively inhibited the growth of melanoma cancer cells, with an IC(50) of 25 ± 0.09 µg/mL. Additionally, ACV demonstrated a significant cytotoxicity at approximately 20 µg/mL in the melanoma cancer cell line, indicating its potential repurposing for skin cancer treatment. Based on these findings, it can be suggested that the RC-SS complex could be an effective drug delivery carrier for localized cancer therapy. Furthermore, the results of an in silico study suggested the addition of chitosan to the formulation for a more effective drug delivery. Energy and interaction analyses using various modules in a material studio demonstrated the high stability of the composite comprising red clay, sucrose stearate, chitosan and ACV. Thus, it could be concluded that the utilization of the red clay-based drug delivery system is a promising strategy to improve the effectiveness of targeted cancer therapy.
format Online
Article
Text
id pubmed-10383537
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103835372023-07-30 Development of a Novel Red Clay-Based Drug Delivery Carrier to Improve the Therapeutic Efficacy of Acyclovir in the Treatment of Skin Cancer Francis, Arul Prakash Ahmad, Aftab Nagarajan, Sri Durga Devi Yogeeswarakannan, Harish Sundar Sekar, Krishnaraj Khan, Shah Alam Meenakshi, Dhanalekshmi Unnikrishnan Husain, Asif Bazuhair, Mohammed A. Selvasudha, Nandakumar Pharmaceutics Article Acyclovir (ACV) is a promising candidate for drug repurposing because of its potential to provide an effective treatment for viral infections and non-viral diseases, such as cancer, for which limited treatment options exist. However, its poor physicochemical properties limit its application. This study aimed to formulate and evaluate an ACV-loaded red clay nanodrug delivery system exhibiting an effective cytotoxicity. The study focused on the preparation of a complex between ACV and red clay (RC) using sucrose stearate (SS) (nanocomplex F1) as an immediate-release drug-delivery system for melanoma treatment. The synthesized nanocomplex, which had nanosized dimensions, a negative zeta potential and the drug release of approximately 85% after 3 h, was found to be promising. Characterization techniques, including FT-IR, XRD and DSC-TGA, confirmed the effective encapsulation of ACV within the nanocomplex and its stability due to intercalation. Cytotoxicity experiments conducted on melanoma cancer cell lines SK-MEL-3 revealed that the ACV release from the nanocomplex formulation F1 effectively inhibited the growth of melanoma cancer cells, with an IC(50) of 25 ± 0.09 µg/mL. Additionally, ACV demonstrated a significant cytotoxicity at approximately 20 µg/mL in the melanoma cancer cell line, indicating its potential repurposing for skin cancer treatment. Based on these findings, it can be suggested that the RC-SS complex could be an effective drug delivery carrier for localized cancer therapy. Furthermore, the results of an in silico study suggested the addition of chitosan to the formulation for a more effective drug delivery. Energy and interaction analyses using various modules in a material studio demonstrated the high stability of the composite comprising red clay, sucrose stearate, chitosan and ACV. Thus, it could be concluded that the utilization of the red clay-based drug delivery system is a promising strategy to improve the effectiveness of targeted cancer therapy. MDPI 2023-07-10 /pmc/articles/PMC10383537/ /pubmed/37514105 http://dx.doi.org/10.3390/pharmaceutics15071919 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Francis, Arul Prakash
Ahmad, Aftab
Nagarajan, Sri Durga Devi
Yogeeswarakannan, Harish Sundar
Sekar, Krishnaraj
Khan, Shah Alam
Meenakshi, Dhanalekshmi Unnikrishnan
Husain, Asif
Bazuhair, Mohammed A.
Selvasudha, Nandakumar
Development of a Novel Red Clay-Based Drug Delivery Carrier to Improve the Therapeutic Efficacy of Acyclovir in the Treatment of Skin Cancer
title Development of a Novel Red Clay-Based Drug Delivery Carrier to Improve the Therapeutic Efficacy of Acyclovir in the Treatment of Skin Cancer
title_full Development of a Novel Red Clay-Based Drug Delivery Carrier to Improve the Therapeutic Efficacy of Acyclovir in the Treatment of Skin Cancer
title_fullStr Development of a Novel Red Clay-Based Drug Delivery Carrier to Improve the Therapeutic Efficacy of Acyclovir in the Treatment of Skin Cancer
title_full_unstemmed Development of a Novel Red Clay-Based Drug Delivery Carrier to Improve the Therapeutic Efficacy of Acyclovir in the Treatment of Skin Cancer
title_short Development of a Novel Red Clay-Based Drug Delivery Carrier to Improve the Therapeutic Efficacy of Acyclovir in the Treatment of Skin Cancer
title_sort development of a novel red clay-based drug delivery carrier to improve the therapeutic efficacy of acyclovir in the treatment of skin cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383537/
https://www.ncbi.nlm.nih.gov/pubmed/37514105
http://dx.doi.org/10.3390/pharmaceutics15071919
work_keys_str_mv AT francisarulprakash developmentofanovelredclaybaseddrugdeliverycarriertoimprovethetherapeuticefficacyofacyclovirinthetreatmentofskincancer
AT ahmadaftab developmentofanovelredclaybaseddrugdeliverycarriertoimprovethetherapeuticefficacyofacyclovirinthetreatmentofskincancer
AT nagarajansridurgadevi developmentofanovelredclaybaseddrugdeliverycarriertoimprovethetherapeuticefficacyofacyclovirinthetreatmentofskincancer
AT yogeeswarakannanharishsundar developmentofanovelredclaybaseddrugdeliverycarriertoimprovethetherapeuticefficacyofacyclovirinthetreatmentofskincancer
AT sekarkrishnaraj developmentofanovelredclaybaseddrugdeliverycarriertoimprovethetherapeuticefficacyofacyclovirinthetreatmentofskincancer
AT khanshahalam developmentofanovelredclaybaseddrugdeliverycarriertoimprovethetherapeuticefficacyofacyclovirinthetreatmentofskincancer
AT meenakshidhanalekshmiunnikrishnan developmentofanovelredclaybaseddrugdeliverycarriertoimprovethetherapeuticefficacyofacyclovirinthetreatmentofskincancer
AT husainasif developmentofanovelredclaybaseddrugdeliverycarriertoimprovethetherapeuticefficacyofacyclovirinthetreatmentofskincancer
AT bazuhairmohammeda developmentofanovelredclaybaseddrugdeliverycarriertoimprovethetherapeuticefficacyofacyclovirinthetreatmentofskincancer
AT selvasudhanandakumar developmentofanovelredclaybaseddrugdeliverycarriertoimprovethetherapeuticefficacyofacyclovirinthetreatmentofskincancer